An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells

MUC1 mucin is aberrantly glycosylated and overexpressed in a number of epithelial malignancies and is therefore a promising tumour-associated antigen for target-directed immunotherapy of a panel of malignant diseases. In MUC1-positive tumours, MHC class I expession is frequently downregulated and MU...

Descripción completa

Detalles Bibliográficos
Autores principales: Heuser, C, Ganser, M, Hombach, A, Brand, H, Denton, G, Hanisch, F-G, Abken, H
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376954/
https://www.ncbi.nlm.nih.gov/pubmed/12966437
http://dx.doi.org/10.1038/sj.bjc.6601267

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376954/
https://www.ncbi.nlm.nih.gov/pubmed/12966437
http://dx.doi.org/10.1038/sj.bjc.6601267

Ejemplares similares